Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Mvrix Co. Ltd. has 1 pending office action currently assigned to FAY, ZOHREH ALEMZADEH. As the busiest examiner for the portfolio, FAY, ZOHREH ALEMZADEH is responsible for this 1 pending action. The prosecution involves 1 distinct examiner and 0 distinct art units. To advance the portfolio, the applicant must resolve the 1 pending office action with this single examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
| ANTHOPOLOS, PETER | 1 | 57.4% | +58.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18287576 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VIRUS INFECTIONS, COMPRISING POLYMER NANODISCS | ANTHOPOLOS, PETER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18287576 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VIRUS INFECTIONS, COMPRISING POLYMER NANODISCS | ANTHOPOLOS, PETER | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18839970 | NANODISC COMPRISING ANGIOTENSIN CONVERTING ENZYME 2 | FAY, ZOHREH ALEMZADEH | — | §103 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18287576 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VIRUS INFECTIONS, COMPRISING POLYMER NANODISCS | ANTHOPOLOS, PETER | 1611 | §102§112Other | Final Rejection | — | Pending | Oct 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial